Tag: MSB

ASX stocks short squeeze shorted

What are the ASX stocks vulnerable to a ‘short squeeze’?

Could the ASX become subject to the same trading shenanigans in the US which put a rocket up the share price of struggling video outlet operator GameStop and then the silver market. It’s certainly ...
Mesoblast ASX MSB Oncologic Drugs Advisory Committee ODAC remestemcel-L RYONCIL

Mesoblast’s lead drug candidate achieves major regulatory milestone after US FDA vote

Shares in Australian biotech midcap Mesoblast (ASX: MSB) have hit their highest point in more than six years today, following the US Food and Drug Administration’s Oncological Drugs Advisory Committee...
ASX biotech stocks COVID-19 life science

ASX biotech stocks benefiting from the COVID-19 story

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Natural...
Mesoblast ASX MSB revenues remestemcel-L Ryoncil GvHD

Mesoblast sees strong revenue growth as maintains busy clinical program with upcoming Ryoncil launch

In an interim performance update focusing on the past nine months, dual-listed cellular medicines company Mesoblast (ASX: MSB) reported it had achieved a “strong financial position” and made progress ...
Mesoblast ASX MSB remestemcel-L drug COVID-19 survival rates ventilator

Mesoblast’s remestemcel-L drug could boost COVID-19 survival rates

Mesoblast’s (ASX: MSB) advanced remestemcel-L drug could potentially boost the survival rate of critically ill COVID-19 patients who have developed acute respiratory distress syndrome, with initial re...
Mesoblast acute respiratory distress syndrome ARDS COVID-19 ASX MSB FDA

Mesoblast’s remestemcel-L receives FDA IND clearance for treating COVID-19 patients with acute respiratory distress

Regenerative medicine company Mesoblast (ASX: MSB) has received US Food and Drug Administration Investigational New Drug (IND) clearance for its remestemcel-L treatment to be used in COVID-19 patients...
Mesoblast COVID-19 coronavirus lung disease allogeneic mesenchymal stem cell ASX MSB

Mesoblast to trial anti-inflammatory infusions in COVID-19 patients with respiratory distress

Mesoblast (ASX: MSB) is the latest ASX company to potentially benefit commercially from the coronavirus global epidemic after revealing it would be evaluating its anti-inflammatory product in COVID-19...
Mesoblast ASX MSB manufacturing agreement Lonza allogeneic cell therapy

Mesoblast signs manufacturing agreement with Lonza, prepares for US launch

Allogeneic cellular medicines company Mesoblast (ASX: MSB) is on track to commence manufacturing of its lead product candidate remestemcel-L courtesy of a manufacturing agreement with Swiss-listed che...